BIO
Bio Rad Laboratories Inc
Price:  
302.02 
USD
Volume:  
173,117.00
United States | Life Sciences Tools & Services
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

BIO WACC - Weighted Average Cost of Capital

The WACC of Bio Rad Laboratories Inc (BIO) is 8.6%.

The Cost of Equity of Bio Rad Laboratories Inc (BIO) is 9.30%.
The Cost of Debt of Bio Rad Laboratories Inc (BIO) is 5.50%.

Range Selected
Cost of equity 8.00% - 10.60% 9.30%
Tax rate 22.20% - 22.60% 22.40%
Cost of debt 4.00% - 7.00% 5.50%
WACC 7.4% - 9.9% 8.6%
WACC

BIO WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.9 1.02
Additional risk adjustments 0.0% 0.5%
Cost of equity 8.00% 10.60%
Tax rate 22.20% 22.60%
Debt/Equity ratio 0.14 0.14
Cost of debt 4.00% 7.00%
After-tax WACC 7.4% 9.9%
Selected WACC 8.6%

BIO's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BIO:

cost_of_equity (9.30%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.9) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.